Americans love their four-legged friends.
If you’re inclined, you can treat your pet to an impressive array of goods and services: spa beauty treatments, gourmet and organic foods and treats, top-flight veterinary care (privately insured, of course), designer pet clothing – the only limit is the depth of your pocket.
As you can imagine, that doting approach to pet ownership is very lucrative for the companies on the supply side.
Americans will spend an estimated $75.3 billion on their pets this year alone. PetSmart Inc. (NASDAQ: PETM) boasts a market cap north of $8 billion. There are not one but two “pet sector” exchange-traded funds (ETFs) available to buy, tracking a deep roster of publicly traded pet companies and service providers.
And now, Fido and Mittens can enjoy a regular regimen of CBD, with all the benefits that entails.
Cannabis companies with the vision and foresight to cash in on this trend are rushing to cater to it.
The good news is that if you’re following along with my recommendations, you already own one of the biggest, richest players in the all-new “pet CBD” segment…
Cannabis for Critters Is Big Business (and It’s Getting Bigger)
As we’ve seen, people all over are turning to CBD and other cannabis-based medicines to treat aches and pains, anxiety, depression, and a whole host of other ailments.
Americans, always willing to part with a buck on their pets’ behalf, want to do the same for their pets.
SIT THIS ONE OUT and you could miss an American economic revolution that could send three little pot stocks soaring up to 1,000%. Click here to see why…
From helping pets remain calm during an airplane flight to even potentially helping to stop seizures, CBD oils and treats have the potential to drastically improve the quality of a pet’s life.
Of that predicted $75.4 billion pet-care spend, some $16 billion went to supplies and over-the-counter medicine; around $18 billion will go to veterinary care.
Clearly, any executive worth his or her paycheck would want to capture a share of that. That CBD acceptance is unfolding as a global trend right now; is fortuitous timing.
And Canopy Growth Corp. (NYSE: CGC) – a company I’ve called “The Microsoft of Weed” – is best positioned to cash in on the trend.
Pet CBD Is a Very Shrewd Move for This New Business Team
Canopy will be the biggest player in the cannabis sector, and it certainly has the cash and vision to do what it wants in the pet med space.
Like teaming up with Martha Stewart to dominate the niche.
Yes, Martha Stewart – she joined Canopy in an advisory role this past winter to help it develop CBD products for animals.
It makes more sense than you might think at first. As the story goes, a large rock fell on Martha’s toe and hurt her badly. Her friend, rapper and legendary cannabis connoisseur Snoop Dogg, introduced her to CBD-infused topicals to help ease the pain.
Whatever happened, it made Stewart a believer.
Now, Martha Stewart’s once–$2 billion empire isn’t what it used to be. Her Martha Stewart Living Omnimedia company was delisted from the New York Stock Exchange, and scooped up for $353 million in cash by Sequential Brands Group Inc. (NASDAQ: SQBG) back in 2015.
But her Martha Stewart brand is still worth a lot, and she still enjoys universal recognition, even if she’s no longer the sole arbiter of good taste she was at the start of the millennium.
The move into CBD is a savvy and likely very lucrative move for Stewart, and one that could go a fair distance to recapturing her old footprint.
The partnership is smart for smart for Martha Stewart, good for her brand, and a huge win for Canopy. It’s great news for Canopy shareholders like us.
There’s another thing to consider – call it a “fringe benefit.”
Remember that in 1969, just 12% of Americans supported cannabis legalization, according to Pew Research. As of 2017, that number has climbed to 64% of Americans who support legalization.
And now, in the person of Martha Stewart, with her wholesome, domestic, “do it yourself” image, the cannabis industry has entrée into American homes like never before.
That’s a profit catalyst if ever there was one.
I know a lot of newer investors view Canopy stock as expensive around $45, but a lot of people thought Microsoft Corp. (NASDAQ: MSFT) stock was expensive on May 22, 2009, when it was trading for $19.75 per share.
Accounting for stock splits, a $10,000 investment at $19.75 a share is now worth roughly $70,000 – and that’s without the dividends being reinvested.
Make no mistake: If you think Canopy stock is too pricey today, just wait till you see how much you’ll have to pay for one share in 10 years!
These 3 Stocks Are the Key to 2019’s Greatest Profits
We expect nothing short of historic profits by the end of the year.
But not all pot stocks will hand you life-changing wins. In fact, often the companies making headlines are least likely to see the biggest gains.
These three stocks, on the other hand, are flying under the radar… for now. Each of them could see exponential stock price acceleration at any moment, and if you get in before that happens, you could turn a token stake into a lifetime of wealth.
I don’t know of any other sector providing anywhere near this level of growth now.
Follow Money Morning on Facebook and Twitter.
About Money Morning: Money Morning gives you access to a team of ten market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.To get full access to all Money Morning content, click here.
Disclaimer: © 2019 Money Morning and Money Map Press. All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning. 16 W. Madison St. Baltimore, MD, 21201.